Today: 2 July 2026
Browse Category

NYSE:PFE 27 December 2025 - 3 January 2026

Pfizer stock today: PFE slips as report flags 2026 U.S. drug price hikes

Pfizer stock today: PFE slips as report flags 2026 U.S. drug price hikes

NEW YORK, January 1, 2026, 20:51 ET — Market closed Pfizer Inc shares last traded at $24.90, down 0.4% from the previous close, with U.S. markets closed on Thursday for the New Year’s Day holiday. Reuters reported Pfizer is leading a new round of U.S. list-price increases for 2026, planning hikes on around 80 drugs and vaccines — including a 15% rise for its COVID-19 shot Comirnaty — as drugmakers overall line up price increases on at least 350 branded medicines, with a median hike of about 4%. “They really just nibble around the margins,” said Dr. Benjamin Rome, a health policy researcher at Brigham and Women’s Hospital, while Pfizer said its average increase for innovative medicines and vaccines would be below inflation. Reuters
2 January 2026
···
Pfizer stock today: PFE in focus as 2026 U.S. drug price hikes kick off — what to watch next

Pfizer stock today: PFE in focus as 2026 U.S. drug price hikes kick off — what to watch next

NEW YORK, January 1, 2026, 05:20 ET — Market closed. Pfizer Inc is in focus after annual U.S. drug pricing changes for 2026 included increases on some of its medicines, a politically sensitive topic heading into the new year. Pfizer shares last closed down 0.36% at $24.90 on Wednesday after trading between $24.88 and $25.02, with about 29.4 million shares changing hands.
1 January 2026
··
Pfizer stock dips after-hours as 2026 drug price hike list puts PFE in the spotlight

Pfizer stock dips after-hours as 2026 drug price hike list puts PFE in the spotlight

NEW YORK, December 31, 2025, 18:50 ET — After-hours Pfizer Inc. shares fell about 0.4% to $24.90 in after-hours trading on Wednesday, after a report said the drugmaker is leading a wave of U.S. list-price increases set for 2026. The data, compiled by healthcare research firm 3 Axis Advisors, showed drugmakers plan hikes on at least 350 branded medicines, with Pfizer accounting for around 80 increases, including a 15% rise for its COVID vaccine Comirnaty. “They really just nibble around the margins,” said Dr. Benjamin Rome, a health policy researcher at Brigham and Women’s Hospital in Boston. Reuters
1 January 2026
···
Pfizer stock today: PFE edges up after TD Cowen sticks with Hold as investors size up 2026 outlook

Pfizer stock today: PFE edges up after TD Cowen sticks with Hold as investors size up 2026 outlook

NEW YORK, December 30, 2025, 13:50 ET — Regular session Pfizer Inc shares were up about 0.1% at $25.03 in afternoon trading on Tuesday, after moving between $24.92 and $25.10. TD Cowen reiterated its Hold rating and kept a $30 price target, pointing to negative trends in its model through 2030 despite the stock’s dividend yield near 7%. Investing.com
30 December 2025
··
Pfizer filings spotlight big portfolio shifts as Live Oak slashes stake 92%

Pfizer filings spotlight big portfolio shifts as Live Oak slashes stake 92%

Live Oak Private Wealth LLC cut its stake in Pfizer by 92.5% in the third quarter, selling 216,868 shares and ending the period with 17,627 shares, a regulatory filing showed. MarketBeat+2SEC+2 The disclosures matter because quarterly holdings reports are one of the few windows investors get into how money managers were positioned in major stocks heading into the final stretch of the year. The filings can signal shifting conviction in Pfizer, a high-profile name in U.S. healthcare. MarketBeat+2MarketBeat+2
29 December 2025
··
Pfizer Stock (NYSE: PFE) Holds Near $25 as Markets Close for the Weekend: Latest News, Analyst Targets, and What to Watch Monday

Pfizer Stock (NYSE: PFE) Holds Near $25 as Markets Close for the Weekend: Latest News, Analyst Targets, and What to Watch Monday

NEW YORK, Dec. 28, 2025, 2:50 p.m. ET — U.S. stock market closed. Pfizer Inc. heads into the final week of 2025 with its shares hovering in the mid-$20s — a level Wall Street has increasingly framed as a “show-me” zone for investors who want evidence that Pfizer can navigate the post-COVID comedown and looming patent expirations while rebuilding growth through oncology and obesity-focused deals.
28 December 2025
··
Pfizer Stock (PFE) Update: Shares Hold Near $25 Into Year-End as Investors Weigh 2026 Guidance, Dividend, and Pipeline Catalysts

Pfizer Stock (PFE) Update: Shares Hold Near $25 Into Year-End as Investors Weigh 2026 Guidance, Dividend, and Pipeline Catalysts

NEW YORK, Dec. 27, 2025, 3:07 p.m. ET — Market closed Pfizer Inc. is heading into the final trading days of 2025 with its stock still anchored in the mid-$20s, a range that has increasingly defined sentiment around the pharmaceutical giant as Wall Street debates two competing narratives: near-term pressure from fading COVID-era revenues and patent expirations, versus a longer-term rebuild driven by oncology and newer growth categories such as obesity.
27 December 2025
···
1 … 3 4 5 6 7 … 11

Stock Market Today

  • Cramer Sees Moderna's Pipeline Opening Up Beyond Covid
    July 1, 2026, 7:50 PM EDT. CNBC's Jim Cramer said on Mad Money that Moderna now looks different than during the Covid rush, with a cancer pipeline and vaccines reaching outside infectious diseases. He sees many programs still years out but calls for buying pullbacks, pointing to Moderna's track to profits and new data from late-stage cancer trials-like the melanoma combo trial with Merck's Keytruda. Moderna shares have jumped almost 150% this year but still trade under pandemic highs. Cramer also mentions fresh regulatory wins, including FDA advisory backing for its flu shot and a European nod for its combined Covid-flu vaccine.
Go toTop